Hey All,
Clarity 1 results are out. In mild disease with COVID-19 & this was with ARB only, not DMX-200 on top of ARB. So it’s not our trial (Clarity 2.0). Need to read for context.
https://www.bmj.com/content/379/bmj-2022-072175
But as I suspected earlier on, large platform trials such as REMAP CAP & others with NHMRC already involved with, will collaborate on data collected as per WHO standards, which I also suspect will happen with DMX-200 data in hospitalised patients (moderate-severe state). Need to look at demographics of recruitment & all this paper. I’m not put off by this at all in ARB alone in mildly sick patients. No wonder the criteria was changed to hospitalised & requiring O2 for Clarity 2.
Now to look at DXB latest presentation, sounds positive. Thanks for the posts Guys!
- Forums
- ASX - By Stock
- Ann: CLARITY 2.0 COVID-19 Study Concludes Recruitment
Hey All, Clarity 1 results are out. In mild disease with...
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M |
Open | High | Low | Value | Volume |
41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 83901 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.395 |
4 | 60000 | 0.390 |
7 | 171788 | 0.385 |
8 | 327657 | 0.380 |
4 | 209342 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 9924 | 2 |
0.410 | 103132 | 2 |
0.415 | 132474 | 5 |
0.420 | 108356 | 2 |
0.425 | 60000 | 2 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |